natgillin/translations-raw huggingface dataset:
Patienter med hjernemetastaser i anamnesen, aktiv autoimmun sygdom eller sygdomstilstande, der krævede systemisk immunsuppression, blev udelukket fra de kliniske studier med nivolumab eller nivolumab i kombination med ipilimumab (se pkt.
Patients with any history of or concurrent brain metastases, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the clinical trials of nivolumab or nivolumab in combination with ipilimumab (see sections 4.5 and 5.1).
Sikkerheden og virkningen af nivolumab 3 mg/kg som enkeltstof til behandling af fremskreden eller metastatisk ikke-planocellulær NSCLC blev undersøgt i et randomiseret, åbent fase 3-studie (CA209057).
The safety and efficacy of nivolumab 3 mg/kg as a single agent for the treatment of advanced or metastatic non-squamous NSCLC were evaluated in a phase 3, randomised, open-label study (CA209057).
Den anbefalede dosis OPDIVO er enten nivolumab 240 mg hver 2. uge eller 480 mg hver 4. uge (se pkt.
Thereafter the recommended dose of OPDIVO is 240 mg given every 2 weeks or 480 mg given every 4 weeks (single-agent phase).
Laboratorietestabnormiteter
Laboratory abnormalities
Resolution forekom hos 428 patienter (63,8 %) med en mediantid til resolution på 17,1 uger (0,1-150,0+).
Resolution occurred in 428 patients (63.8%) with a median time to resolution of 17.1 weeks
Immunrelaterede hudreaktioner
Immune-related skin adverse reactions
De vigtigste sekundære effektparametre var investigatorvurderet PFS og ORR.
The primary efficacy outcome measure was OS. Key secondary efficacy outcome measures were investigator-assessed PFS and ORR.
Dette efterfølges af fase 2, hvor nivolumab administreres som monoterapi intravenøst, som enten 240 mg hver 2. uge.
This is then followed by a second phase in which nivolumab monotherapy is administered intravenously at either 240 mg every 2 weeks or at 480 mg every 4 weeks, as presented in Table 2.
Betændelseslignende reaktion i nerverne (som medfører følelsesløshed, svaghed, snurrende fornemmelse eller brændende smerter i arme og ben), svimmelhed Øjenbetændelse (med rødme og smerter), sløret syn Hurtig hjerterytme (puls)
Inflammation of the nerves (causing numbness, weakness, tingling or burning pain of the arms and legs), dizziness
Progressionsfri overlevelse Rate (95 % CI) ved 12 måneder “+”markerer en censoreret observation.
Range Median time to response Months (range) Median duration of follow-up Months (range) Progression-free survival Rate (95% CI) at 12 months “+” denotes a censored observation.
Der er observeret alvorligt udslæt, som kan være immunrelateret, ved behandling med nivolumab i kombination med ipilimumab og, mindre hyppigt, med nivolumab som monoterapi (se pkt.
Severe rash has been observed with nivolumab in combination with ipilimumab and, less commonly, with nivolumab as monotherapy (see section 4.8).
CA209205 kohorte B og CA209039 (n = 95)
CA209205 Cohort B and CA209039
Ved grad 4 diarre eller colitis skal nivolumab eller nivolumab i kombination med ipilimumab seponeres permanent, og kortikosteroid initieres med en dosis ækvivalent med 1-2 mg/kg/dag methylprednisolon.
For Grade 4 diarrhoea or colitis, nivolumab or nivolumab in combination with ipilimumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.
Svær nefritis og nedsat nyrefunktion er observeret med monoterapi eller nivolumab i kombination med ipilimumab (se pkt.
Severe nephritis and renal dysfunction have been observed with monotherapy treatment or nivolumab in combination with ipilimumab (see section 4.8).
Hos RCC-patienter, der blev behandlet med nivolumab 3 mg/kg i kombination med ipilimumab 1 mg/kg, var andelen af patienter, som oplevede en forværring fra baseline til en grad 3 eller 4 abnorm laboratorietest, følgende: 3,0 % med anæmi (alle grad 3), 0,7 % med trombocytopeni, 0,6 % med leukopeni, 5,1 % med lymfopeni, 1,1 % med neutropeni, 2,0 % med forhøjet alkalisk phosphatase, 4,8 % med forhøjet ASAT, 6,5 % med forhøjet ALAT, 1,1 % med forhøjet total-bilirubin, 2,1 % med forhøjet kreatinin, 7,2 % med hyperglykæmi, 1,8 % med hypoglykæmi, 12,2 % med forhøjet amylase,
In patients treated with nivolumab 3 mg/kg in combination with ipilimumab 1 mg/kg in RCC, the proportion of patients who experienced a worsening from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 3.0% for anaemia (all Grade 3), 0.7% for thrombocytopaenia, 0.6% for leucopoenia, 5.1% for lymphopaenia, 1.1% for neutropaenia, 2.0% for increased alkaline phosphatase, 4.8% for increased AST, 6.5% for increased ALT, 1.1% for increased total bilirubin, 2.1% for increased creatinine, 7.2% for hyperglycaemia, 1.8% for hypoglycemia, 12.2% for increased amylase, 20.1% for increased lipase, 0.4% for hypocalcaemia, 1.3% for hypercalcaemia, 2.4% for hyperkalemia, 1.1% for hypermagnesaemia, 0.4% for hypomagnesaemia 1.9% for hypokalaemia, and 9.9% for hyponatraemia.
Ved grad 4 stigning i serumkreatinin skal nivolumab eller nivolumab i kombination med ipilimumab seponeres permanent, og kortikosteroid bør initieres med en dosis ækvivalent med 1-2 mg/kg/dag methylprednisolon.
For Grade 4 serum creatinine elevation, nivolumab or nivolumab in combination with ipilimumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.
Nivolumab+ipilimumab versus ipilimumab - hazard ratio: 0,35 (0,22; 0,55) Nivolumab versus ipilimumab - hazard ratio: 0,41 (0,27; 0,62) Nivolumab+ipilimumab versus nivolumab - hazard ratio: 0,87 (0,54; 1,41)
Nivolumab+Ipilimumab vs. Ipilimumab - hazard ratio: 0.35 (0.22, 0.55) Nivolumab vs. Ipilimumab - hazard ratio: 0.41 (0.27, 0.62) Nivolumab+Ipilimumab vs. Nivolumab - hazard ratio: 0.87 (0.54, 1.41)
Median (95 % CI) Hyppighed (95 % CI) Ved 6 måneder Ved 12 måneder
Median (95% CI) Rate (95% CI) At 6 months At 12 months
Kronisk sygdom i leddene (spondylartropati), sygdom, hvor immunsystemet angriber de kirtler, der producerer kropsvæsker som tårer og spyt (Sjögrens syndrom), muskelsmerter, ømme eller svage muskler, som ikke skyldes fysisk aktivitet (myopati), en betændelseslignende reaktion i musklerne (myositis), stivhed i muskler og led, muskelkramper (rabdomyolyse), betændelseslignende reaktion (inflammation) i musklerne med smerter og stivhed (polymyalgia rheumatica)
Intestinal perforation, inflammation of the stomach (gastritis), inflammation of the duodenum Skin disease with thickened patches of red skin, often with silvery scales (psoriasis), severe condition of the skin that causes red, often itchy spots, similar to the rash of measles, which starts on the limbs and sometimes on the face and the rest of the body (erythema multiforme) Severe and possibly fatal peeling of the skin (Stevens-Johnson syndrome) Chronic disease of joints (spondyloarthropathy), disease in which the immune system attacks the glands that make moisture for the body, such as tears and saliva (Sjogren's syndrome), aching muscles, muscle tenderness of weakness, not caused by exercise (myopathy), inflammation of the muscles (myositis), stiffness in muscles and joints, muscle spasm (rhabdomyolysis), inflammation of the muscles causing pain or stiffness (polymyalgia rheumatica) Inflammation of the kidney
Almindelig infusionsrelateret reaktionc, overfølsomhedc Sjælden anafylaktisk reaktionc Ikke kendt Afstødning af transplanterede solide organerh, sarkoidoseh
Uncommon sarcoidosis Not known solid organ transplant rejectionh Endocrine disorders Very common hypothyroidism hypothyroidism, hyperthyroidism
Behandling efter initial investorvurderet RECIST version 1,1-defineret progression var tilladt, hvis patienten efter investigatord vurdering oplevede kliniske fordele og tolererede studielægemidlet.
Treatment beyond initial investigator-assessed RECIST version 1.1-defined progression was permitted in patients receiving nivolumab, if the patient had a clinical benefit and was tolerating study drug, as determined by the investigator.
PD-L1 ≥ 1 %, PD-L1+ TAIC udbredtd
PD-L1 ≥ 1%, PD-L1+ TAIC abundantd
Oddsratio (95 % CI)
Odds Ratio (95% CI)
De vigtigste sekundære effektparametre var investigatorvurderet ORR og PFS.
The primary efficacy outcome measure was OS. Key secondary efficacy outcome measures were investigator-assessed ORR and PFS.
Sikkerheden og virkningen af nivolumab 3 mg/kg som enkeltstof til behandling af fremskreden eller metastatisk planocellulær NSCLC blev undersøgt i et randomiseret, åbent fase 3-studie (CA209017).
The safety and efficacy of nivolumab 3 mg/kg as a single agent for the treatment of advanced or metastatic squamous NSCLC were evaluated in a phase 3, randomised, open-label study (CA209017).
Det endokrine system Meget almindelig hypotyroidisme hypotyroidisme, hypertyroidisme
Common hypothyroidism, hyperthyroidism
Renalcellekarcinom
Renal Cell Carcinoma
Se i pkt.
from the study.
Smerter i muskler og knogler (muskuloskeletale smerter) og led (artralgi) Feber, væskeansamlinger (hævelse)
Inflammation of the muscles causing pain or stiffness (polymyalgia rheumatica), inflammation of the joints (arthritis)
PD-L1 < 1 %, PD-L1+ TAIC udbredtd
PD-L1 < 1%, PD-L1+ TAIC abundantd
Øjne Almindelig uveitis, sløret syn sløret syn
Eye disorders Common uveitis, blurred vision blurred vision
Samlet overlevelse (måneder) Antal forsøgspersoner i risikogruppe Nivolumab 3 mg/kg Docetaxel ──Δ─── Nivolumab 3 mg/kg (hændelser: 190/292), median-OS og 95 % CI: 12,19 (9,66; 14,98) - - -- - - Docetaxel (hændelser: 223/290), median-OS og 95 % CI: 9,36 (8,05; 10,68)
Docetaxel ──Δ─── Nivolumab 3 mg/kg (events: 190/292), median and 95% CI: 12.19 (9.66, 14.98) - - -- - - Docetaxel (events: 223/290), median and 95% CI: 9.36 (8.05, 10.68) The trial demonstrated a statistically significant improvement in OS for patients randomised to nivolumab as compared with docetaxel at the prespecified interim analysis when 413 events were observed (93% of the planned number of events for final analysis).
OPDIVO 10 mg/ml koncentrat til infusionsvæske, opløsning.
NAME OF THE MEDICINAL PRODUCT OPDIVO 10 mg/mL concentrate for solution for infusion.
Polyneuropati, autoimmun neuropati (herunder facial og nervus abducens parese) Sjælden Guillain-Barré syndrom, demyelinisering, myastenisk syndrom, encephalitisa,c Øjne
Guillain-Barré syndrome, demyelination, myasthenic syndrome, encephalitisa,c
Samlet overlevelse Hændelser
Overall survivala Events
Mediantid til indtræden var 2,1 måneder (0,027,6).
Median time to onset was 2.1 months (range: 0.0-27.6).
Ved grad 3 eller 4 forhøjelse af aminotransferase eller total-bilirubin seponeres nivolumab eller nivolumab i kombination med ipilimumab permanent, og kortikosteroid initieres med en dosis ækvivalent med 1-2 mg/kg/dag methylprednisolon.
For Grade 3 or 4 transaminase or total bilirubin elevation, nivolumab or nivolumab in combination with ipilimumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.
Median (95 % CI) (måneder) Hyppighed (95 % CI) ved 12 måneder
Median (95% CI) (months) Rate (95% CI) at 12 months
Væskemangel, forhøjet syreindhold i blodet
Infections of the upper respiratory tract
Resolution forekom hos 124 patienter (93,9 %) med en mediantid til resolution på 5,1 uger
Resolution occurred in 124 patients (93.9%) with a median time to resolution of 5.1 weeks (range: 0.1-106.9).
FREMSTILLERENS BATCHNUMMER
Investigator's choice
CA209205 kohorte Ba CA209205 kohorte Ca
CA209205 Cohort Ba CA209039
Sværhedsgrad
Rare
Ikke almindelig sarkoidose Ikke kendt afstødning af transplanterede solide organerh
Not known solid organ transplant rejectionh, sarcoidosish Endocrine disorders
Virkning og anvendelse 2.
What OPDIVO is and what it is used for 2.
Fordelingen af patienter var velbalanceret på tværs behandlingsgrupperne blandt patienter med kvantificerbar PD-L1-tumorekspression.
Among patients with quantifiable tumour PD-L1 expression, the distribution of patients was balanced across the treatment groups.
Betændelseslignende reaktion i tarmene (colitis), mundsår og forkølelsessår (stomatitis), opkastning, mavesmerter, forstoppelse, mundtørhed Pletvise farveændringer af huden (vitiligo), tør hud, hudrødme, unormalt hårtab eller udtynding af håret
Skin colour change in patches (vitiligo), dry skin, redness of the skin, unusual hair loss or thinning Pain in the muscles, bones (musculoskeletal pain) and joints (arthralgia) Fever, oedema (swelling)
Almindelig (kan forekomme hos op til 1 ud af 10 personer) Alvorlig lungeinfektion (lungebetændelse), infektioner i de øvre luftveje, øjenbetændelse (konjunktivitis)
Serious lung infection (pneumonia), infections of the upper respiratory tract, inflammation of the eye (conjunctivitis)
Nerveskade, som medfører følelsesløshed og svaghed (polyneuropati), betændelseslignende reaktion i nerverne som skyldes at kroppen angriber sig selv, som medfører følelsesløshed, svaghed, snurrende fornemmelse eller brændende smerter (autoimmun neuropati) Øjenbetændelse (med rødme og smerter), sløret syn, tørre øjne Hurtig hjerterytme (puls), betændelseslignende reaktion i sækken der ligger omkring hjertet og ophobning af væske omkring hjertet (sygdomme i perikardiet) Væske omkring lungerne
Damage to nerves causing numbness and weakness (polyneuropathy), inflammation of the nerves caused by the body attacking itself, causing numbness, weakness, tingling or burning pain (autoimmune neuropathy)
Responsvarighed hos PR (måneder)c
Duration of response in PR (months) Median (95% CI)
Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer) Alvorlig lungeinfektion (lungebetændelse), bronkitis Øget mængde af bestemte typer hvide blodlegemer Nedsat udskillelse af de hormoner, der dannes i binyrerne (kirtler placeret over nyrerne), nedsat funktion af eller betændelseslignende reaktion i hypofysen (sidder nederst i hjernen), hævelse af skjoldbruskkirtlen, diabetes
Decreased secretion of hormones produced by adrenal glands (glands situated above the kidneys), underactive function (hypopituitarism) or inflammation (hypophysitis) of the pituitary gland situated at the base of the brain, swelling of the thyroid gland, diabetes Dehydration, increased acid levels in the blood
Ikke almindelig pleuraeffusion Mave-tarm-kanalen Meget almindelig colitisa, diarre, opkastning, kvalme, abdominalsmerter diarre, opkastning, kvalme
Very common colitisa, diarrhoea, vomiting, nausea,
Lægemidlet fås som en spot-on, opløsning, i to forskellige koncentrationer (6 % og 12 %) og i tuber med forskellige styrker (15, 30, 45, 60, 120, 240 og 360 mg).
The medicine is available as a spot-on solution in 2 different concentrations (6% and 12%) and in tubes of various strengths (15, 30, 45, 60, 120, 240 and 360 mg).
Chanhold fik en markedsføringstilladelse med gyldighed i hele EU den 17/04/2019.
Chanhold received a marketing authorisation valid throughout the EU on 17 April 2019.
Andre oplysninger om Chanhold
Other information about Chanhold
Yderligere oplysninger om Chanhold findes på agenturets websted under: ema.europa.eu/Find medicines/veterinary/EPAR/chanhold.
Further information on Chanhold can be found on the Agency's website: ema.europa.eu/Find medicines/veterinary/EPAR/chanhold.
Indlægssedlen indeholder detaljerede oplysninger om dosering og behandlingens varighed.
The package leaflet contains detailed information on dosage and duration of treatment.
Hvilke fordele og risici er der forbundet med Chanhold?
What are the benefits and risks of Chanhold?
Som for alle lægemidler fremlagde virksomheden studier af kvaliteten af Chanhold.
As for every medicine, the company provided studies on the quality of Chanhold.
Det Europæiske Lægemiddelagentur konkluderede, at det i overensstemmelse med EU's krav er påvist, at Chanhold er sammenligneligt med Stronghold.
The European Medicines Agency concluded that, in accordance with EU requirements, Chanhold has been shown to be comparable to Stronghold.
Den anvendte styrke og antallet af administrationer afhænger af det behandlede dyrs vægt og art og af typen af parasit.
The strength used and the number of administrations depend on the weight and species of the animal being treated, and the type of parasite.
Oversigt over Chanhold, og hvorfor det er godkendt i EU
An overview of Chanhold and why it is authorised in the EU
Der er allerede gennemført studier af fordelene og risiciene ved det aktive stof i de godkendte anvendelser med referencelægemidlet, Stronghold, og det er ikke nødvendigt at gentage disse med Chanhold.
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Stronghold, and do not need to be repeated for Chanhold.
Det betyder, at Chanhold indeholder det samme aktive stof og virker på samme måde som et "referencelægemiddel", som allerede er godkendt i Den Europæiske Union (EU), og som hedder Stronghold.
This means that Chanhold contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Stronghold.
Der var ikke behov for "bioækvivalensstudier" for at undersøge, om Chanhold optages på samme måde som referencelægemidlet for at give det samme niveau af det aktive stof i blodet.
There was no need for ‘bioequivalence' studies to investigate whether Chanhold is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood.
Da Chanhold er et generisk lægemiddel, anses dets fordele og risici for at være de samme som for referencelægemidlet.
Because Chanhold is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Det skyldes, at sammensætningen af Chanhold er sammenlignelig med referencelægemidlets, og når det påføres huden, forventes det, at det aktive stof i begge produkter optages på samme måde.
This is because the composition of Chanhold is comparable to the reference medicine and when applied to the skin, the active substance in both products is expected to be absorbed in the same way.
Hvorfor blev Chanhold godkendt i EU?
Why is Chanhold authorised in the EU?
Disse forholdsregler er de samme som for referencelægemidlet, eftersom Chanhold er et generisk lægemiddel.
The precautions are the same as for the reference medicine since Chanhold is a generic medicine.
Hvad er Chanhold, og hvad anvendes det til?
What is Chanhold and what is it used for?
Det var derfor agenturets opfattelse, at fordelene ved Chanhold opvejer de identificerede risici som for Stronghold, og at det kan godkendes til anvendelse i EU.
Therefore, the Agency's view was that, as for Stronghold, the benefit of Chanhold outweighs the identified risk and it can be authorised for use in the EU.
Chanhold indeholder det aktive stof selamectin og er et "generisk lægemiddel".
Chanhold contains the active substance selamectin and is a ‘generic medicine'.
Hvis du ønsker flere oplysninger om anvendelsen af Chanhold, kan du læse indlægssedlen eller kontakte din dyrlæge eller dit apotek.
For more information about using Chanhold, see the package leaflet or contact your veterinarian or pharmacist.
Chanhold indeholder selamectin, som er et lægemiddel mod parasitter, der tilhører klassen "avermectin".
Chanhold contains selamectin, which is an antiparasitic medicine that belongs to the ‘avermectin' class.
Der er anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Chanhold, herunder passende forholdsregler, som skal følges af sundhedspersoner og den, der er ejer af eller ansvarlig for dyret.
Safety information has been included in the summary of product characteristics and the package leaflet for Chanhold, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Chanhold er et lægemiddel mod parasitter, der anvendes til behandling og forebyggelse af angreb fra parasitter, der lever på huden eller i pelsen på katte og hunde, såsom lopper og mider, samt til behandling af ormeparasitter, der lever i kroppen.
Chanhold is an antiparasitic medicine used to treat and prevent infestations with parasites that live on the skin or in the fur of cats and dogs, such as fleas and mites, as well as treating worm parasites that live inside the body.
Hvordan er Chanhold blevet undersøgt?
How has Chanhold been studied?
Hvordan virker Chanhold?
How does Chanhold work?
til forebyggelse af hjerteorm hos katte og hunde til behandling af øremider hos katte og hunde til behandling af voksne spolorme og hageorme i tarmene hos katte til behandling af voksne spolorme hos hunde til behandling af angreb med bidende lus hos katte og hunde til behandling af sarcoptesskab hos hunde.
It can also be used as part of a treatment for flea allergy dermatitis (skin inflammation), to prevent heartworm disease in cats and dogs, to treat ear mites in cats and dogs, to treat adult intestinal roundworms and intestinal hookworms in cats, to treat adult intestinal roundworms in dogs, to treat biting lice infestations in cats and dogs, to treat sarcoptic mange (scabies) in dogs.
Hvordan anvendes Chanhold?
How is Chanhold used?
ATCvet-kode: QI06AH08.
ATCvet code: QI06AH08.
Dato for første markedsføringstilladelse: 23/02/2005 Dato for seneste fornyelse af markedsføringstilladelse: 15/01/2010
Date of first authorisation: 23/02/2005 Date of last renewal: 15/01/2010
69800 SAINT-PRIEST FRANKRIG
69800 SAINT-PRIEST FRANCE
I yderst sjældne tilfælde kan hypersensitivitetsreaktion forekomme, der kan kræve passende symptomatisk behandling.
In exceptional circumstances a hypersensitivity reaction may occur, which may require appropriate symptomatic treatment.
Navn og adresse på fremstillere af de biologisk aktive stoffer
Name and address of the manufacturers of the biological active substances
Basisvaccination: - første injektion fra 8-ugersalderen, - anden injektion: 3-4 uger senere.
Primary vaccination course: - first injection: from 8 weeks of age, - second injection: 3 to 4 weeks later.
Produktet reducerer udskillelsen af felin calicivirus ved indtræden af immunitet og i et år efter vaccination.
The product was shown to reduce excretion of feline calicivirus at onset of immunity and for one year after vaccination.
1 cellekultur infektiøs dosis 50%.
1 cell culture infective dose 50%.
Anvendes umiddelbart efter opløsning.
Use immediately after reconstitution.
Særlige forholdsregler til brug hos dyr: Vacciner kun raske dyr.
Special precautions for use in animals: Use in healthy animals only.
Laboratoires Porte des Alpes Rue de l'Aviation
Laboratory of Lyon Porte des Alpes Rue de l'aviation
EU/2/04/051/001 Lyofilisat (10 flasker à 1 dosis) + solvens (10 flasker à 1 ml) EU/2/04/051/002 Lyofilisat (50 flasker à 1 dosis) + solvens (50 flasker à 1 ml)
EU/2/04/051/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/051/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
Særlige forholdsregler der skal træffes af personer, der administrerer lægemidlet til dyr: I tilfælde af selvinjektion ved hændeligt uheld skal der straks søges lægehjælp, og indlægssedlen eller etiketten bør vises til lægen.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Aktiv immunisering af katte, der er 8 uger eller ældre: - mod felin viral rhinotracheitis for at reducere kliniske tegn, - mod calicivirus infektion for at reducere kliniske tegn.
Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs.
Casein hydrolysat Kollagen hydrolysat Dikaliumphosphat Kaliumdihydrogenphosphat Kaliumhydroxid
Casein hydrolysate Collagen hydrolysate Dipotassium phosphate Potassium dihydrogen phosphate Potassium hydroxide Sodium chloride
Under normale omstændigheder kan der af og til forekomme apati og anoreksi samt hypertermi (der sædvanligvis varer 1 til 2 dage).
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).